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he purpose of this article is to present the practicing
sonographer and sonologist with an overview of the
biohazards of ultrasound and guidelines for safe
use. Key words: bioeffects; fetal; mechanical index;
output display standard; thermal index; ultrasound.
Overview 
Ultrasound is an imaging modality that has important
diagnostic value. Although useful in a variety of applica-
tions, diagnostic ultrasound is particularly useful in
prenatal diagnosis. To date, there is no evidence that
diagnostic ultrasound produces harm in humans or the
developing fetus when used properly.
There are, however, an increasing range of ultrasound
studies being performed. Newer technologies can have
higher acoustic output levels than earlier equipment.
Also, subtle or transient effects of diagnostic ultrasound,
such as changes in membrane permeability or neuronal
migration, are not completely understood.
Therefore, diagnostic ultrasound should be used pru-
dently with ultrasound examinations performed only by
trained, competent personnel. To ensure continued
safety, it is essential to maintain an awareness of the
potential for bioeffects, especially with newer equipment
and more sophisticated procedures.
The purpose of this article is to review ultrasound
biosafety considerations for the practicing sonographer
and sonologist as well as to provide references for more
detailed discussion and guidance. There has been con-
siderable debate within the ultrasound bioeffects
community regarding setting specific values for the
mechanical index (MI) and thermal index (TI) to limit
bioeffects risk. There also has been some reluctance in
the bioeffects community to help sonographers and
sonologists make appropriate practical clinical biosafety
decisions because of this debate.
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This article should be viewed as the considered
opinion of the authors and should not be taken
as the position of any professional society or
medical specialty board. This article is an effort
on our part to start a discussion on what consti-
tutes appropriate practical guidance to the sono-
grapher and sonologist regarding acoustic
output values consistent with obtaining diagnos-
tic information while protecting patient welfare. 
Ultrasound Acoustic Output and Bioeffects 
Some tissues, such as those in the developing
embryo and fetus, are particularly sensitive to
energy deposition from many imaging modali-
ties, including ultrasound. Up to 8 weeks after
conception, organogenesis is taking place in the
embryo. This is a period when cell damage might
lead to anomalies or subtle developmental
changes. Fetal effects also vary with the increas-
ing mineralization of developing bone, raising
the potential for heating of sensitive tissues such
as brain and spinal cord, although the increasing
fetal size in later gestation may provide some
additional resistance to thermal insults. The brain
and spinal cord continue to develop through to
the neonatal period, so continued vigilance is
necessary.
The presence of bone within the ultrasound
beam greatly increases the likelihood of a tem-
perature rise due to direct absorption in the bone
itself and conduction of heat from bone to adja-
cent tissues. Generally, the temperature rise is
greatest at bone surfaces and the adjacent soft
tissues. As a result, it also is important to mini-
mize eye exposures in the fetus and adult
because of the relatively low perfusion in the eye,
particularly in the lens, which has a reduced
capability for heat dissipation.
Furthermore, because ultrasound is mechani-
cal energy, the mechanical interaction of sound
with cells and tissues has the potential to pro-
duce nonthermal bioeffects.
Limited information is available regarding pos-
sible subtle biological effects at diagnostic levels
in fetal, pediatric, and adult patients. Therefore,
one should limit acoustic output and exposure
time commensurate with obtaining an accept-
able diagnostic evaluation. At present, there is no
reason to withhold diagnostic scanning, includ-
ing during pregnancy, provided it is medically
indicated and is used prudently by fully trained
operators.1–3 However, it also is important to keep
in mind that the potential for bioeffects also
exists with equipment that is not adjusted prop-
erly or used prudently. 
Standard for Real-time Display of Thermal
and Mechanical Acoustic Output Indices
on Diagnostic Ultrasound Equipment
Before 1976, there were no limits to the permissi-
ble acoustic output from diagnostic ultrasound
equipment. In 1976, the US Food and Drug
Administration (FDA) began regulating medical
devices, including ultrasound, and eventually
developed 4 application-specific exposure limits
(peripheral vascular, 720 mW/cm2; cardiac, 430
mW/cm2; fetal and other, 94 mW/cm2; and oph-
thalmic, 17 mW/cm2).4,5 This regulatory output
level was established on the basis of the predicate
devices in use in the market at that time and the
apparent safety of ultrasound as understood at
that time.
In 1992, at the request of manufacturers and
end users interested in obtaining specific
improvements in the diagnostic capabilities of
ultrasound, the FDA changed this limit to 720
mW/cm2 for all applications except eye scan-
ning. Most prenatal epidemiologic studies on
bioeffects have been based on ultrasound expo-
sures occurring before 1992 with equipment reg-
ulated according to the pre-1992 output limits of
94 mW/cm2. Along with the change in output
limits, the FDA also mandated that machines
capable of producing higher outputs be able to
display to the diagnostician some indication of
the relative potential for ultrasound-induced bio-
effects. This regulation is known as the Standard
for Real-Time Display of Thermal and Mechanical
Acoustic Output Indices on Diagnostic Ultrasound
Equipment, more commonly known as the out-
put display standard (ODS).4,6
The original proposal for implementation of
the ODS was to remove limits on machine out-
put, placing full responsibility on the operator.
Subsequently, it was decided to implement the
ODS with the limits along with some indication
of the acoustic output on the display. Since 1992,
equipment is capable of operating with acoustic
140 J Ultrasound Med 2009; 28:139–150
Ultrasound Biosafety for the Sonographer and Sonologist
jum282online.qxd:Layout 1  1/16/09  4:12 PM  Page 140
outputs of up to 720 mW/cm2 with the specific
acoustic output under the direct control of the
operator and with the expectation that tech-
niques that are as low as reasonably achievable
(ALARA) will be used.
The ODS consists of the MI and the TI. The MI
is an on-screen indicator of the relative potential
for ultrasound to induce an adverse bioeffect
by a nonthermal mechanism. The TI is an on-
screen indicator of the relative potential for a
tissue temperature rise. The TI is a model-based
approach to determine where the maximum
temperature and location in the acoustic field
would be expected on the basis of the imaging
parameters and the acoustic propagation model
selected.
Although not perfect, TI and MI estimates rep-
resent the most practical approach to thermal
and nonthermal risk estimation currently avail-
able. Nevertheless, for the acoustic indices to be
meaningful, the diagnostician must be familiar
with ultrasound safety issues and their implica-
tions for fetal and patient imaging studies.
Implementation of the ODS puts much greater
responsibility for patient safety on the ultra-
sound end user. Adherence to the ALARA princi-
ple also is recommended.
An additional major requirement for accep-
tance of the ODS by the FDA pertains to ade-
quate education of end users. This requires
information about the ODS be provided by the
manufacturer, which is most commonly in the
form of the publication Medical Ultrasound Safety7
from the American Institute of Ultrasound in
Medicine, which is provided with new ultrasound
scanners. However, the broader goal for sonogra-
phers and sonologists should be an understanding
of the potential for bioeffects through initial appli-
cations training by the vendor, ongoing continu-
ing medical education courses, and vigilant daily
awareness of acoustic output. 
Acoustic Physics 
Physical Properties of Ultrasound 
Ultrasound is mechanical energy that propa-
gates longitudinally through elastic media, such
as tissues, creating alternating zones of compres-
sion and rarefaction. Ultrasound imaging typi-
cally uses short pulses (Figure 1) with acoustic
energy reflected back toward the transducer
from interfaces having different acoustic proper-
ties. Typical biomedical ultrasound imaging
parameters are shown in Table 1.8
The acoustic power is the rate of energy pro-
duction. The Système International d’Unités unit
of power is the watt (1 J/s). The acoustic intensi-
ty is the rate of energy flowing through a unit
area6 (watts per square centimeter). Acoustic
output is measured for a variety of pulse condi-
tions with the intensity relationships between
the various measured parameters shown in
Table 2 and Figure 1.
The current FDA output limits for diagnostic
ultrasound are a spatial-peak temporal-average
intensity (ISPTA) less than 720 mW/cm
2. The
acoustic output depends on the output power,
pulse repetition frequency, and scanner operat-
ing mode (eg, B-mode, M-mode, pulsed, or color
or power Doppler imaging).4,9 
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Figure 1. Acoustic pulses showing where and how acoustic output is measured
and reported for a single scan line at the focus of a diagnostic medical ultrasound
system.
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Mechanical Index 
The MI is intended to offer a guide to the likeli-
hood of a nonthermal bioeffect, including cav-
itation, and is related to the intensity of the
pulse.10–18 The MI is defined as the maximum
value of the peak negative pressure divided by
the square root of the acoustic center frequency.
The MI is based on the derated peak rarefaction-
al pressure.*
Cavitation is the phenomenon wherein bub-
bles form in a liquid material when the local
pressure (such as might be produced by the rar-
efaction part of a passing ultrasound wave) falls
below the vapor pressure of the liquid sufficient
to pull the material apart. Cavitation generally
falls into 2 types: (1) inertial or transient cavita-
tion, in which the newly formed bubble rapidly
collapses, producing a shock wave that can be
capable of biological effects; and (2) noninertial
cavitation, in which the bubble oscillates in the
acoustic field and appears to be less likely to pro-
duce biological effects.
Ultrasound contrast agents also can play a role
in cavitation. Ultrasound contrast agents typi-
cally are stable gas-filled microbubbles. Although
cavitation can occur without ultrasound contrast
agents, the presence of microbubbles can in -
crease the probability of cavitation and other
non thermal effects.2,19–21 Animal studies have
shown that ultrasound contrast agents potential-
ly can enhance cavitation and microstreaming
effects, resulting in microvascular damage or
capillary rupture.20,21
Ultrasound contrast agents also have been
associated with induction of premature ventric-
ular contractions in echocardiography using
high-MI pulses. Appropriately triggered excita-
tion can be used to reduce the occurrence of
such effects. In general, the risk of cavitation
increases with an increasing MI.3
The potential for ultrasound nonthermal bio-
hazards exists if equipment is used imprudently.
Damage has been shown in animal models for
tissues having gas pockets at MI values greater
than 0.4. Thus, one should avoid unnecessary
exposure to tissues such as the neonatal lung. As
a general strategy, the MI should be kept as low
as possible while obtaining the necessary diag-
nostic information.
Thermal Index 
The TI is defined as the ratio of the emitted
acoustic power to the power required to raise the
temperature of tissue by 1°C. The TI is intended
to give a rough guide to the magnitude of the
temperature rise that might be produced after a
long exposure, although technically the TI is not
a measure of the precise temperature rise.22,23
A larger TI value represents a higher heating
potential and correspondingly a higher risk (eg, a
TI of 2 means a higher risk than a TI of 1.5 but not
as high a risk as a TI of 3).
There are 3 forms of the TI that may be dis-
played, according to the application: 
1. The thermal index for soft tissue (TIS). This
assumes that the ultrasound beam does not
impinge on bone but only insonates soft tis-
sue, such as in the first trimester. 
2. The thermal index for bone (TIB). This assumes
that the beam impinges on bone at or near its
focus and where appropriate should be dis-
played in the second and third trimesters. 
3. The thermal index for cranial bone (TIC).
This assumes that the transducer front face is
very close to bone, such as when scanning in
neonatal, pediatric, and adult patients. 
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Table 1. Diagnostic Medical Ultrasound Properties
Parameter Value
Speed of sound 1.45–2.1 mm/µsa
Frequency 1–15 MHz
Wavelength 0.1–1.5 mm
Pulse length 3–5 cycles
Attenuation 0.3 dB/(cm-MHz) (derated)
Frame rate up to 150 frames/second (30 frames/second typical)
aNominal scanner values are typically set to 1.54 mm/µs.
* The maximum value of the peak negative pressure anywhere in the ultrasound field measured in water is
reduced by an attenuation factor equal to that which would be produced by a medium having an attenuation
coefficient of 0.3 dB/(cm-MHz) typically referred to as a process called derating. All of the FDA regulatory levels
are specified with derated ISPTA values. 
J Ultrasound Med 2009; 28:139–150142
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The maximum temperature and its location in
the acoustic field for the TIS and TIB would be at
the focal point of the ultrasound beam, but such
is not necessarily the case for the TIC. However,
limitations of the simple models on which the TI
is based mean that TI values may underestimate
the temperature elevation by a factor of 2 or
greater, although more typically, the TI overesti-
mates the temperature.2
A temperature elevation less than 1.5°C likely does
not present a bioeffects risk to the embryo, although
there has been some debate on the threshold
nature of thermal effects.24 A temperature elevation
greater than 4°C for 5 minutes can present a bioef-
fects risk to the embryo.25 Velocity, power, and
pulsed spectral Doppler ultrasound all have the
potential to reach these levels. The TI provides a
guide for the sonographer and sonologist regarding
the magnitude of the temperature increase. 
Acoustic Reporting Requirements 
The acoustic reporting requirements are
implemented by the FDA, which uses a 2-track
approach to marketing clearance: tracks 1 and 3.
Track 1 is for devices that do not follow the ODS
and therefore have application-specific output
limits; track 3 is for devices that conform to the
ODS. There is no longer a track 2.
Systems that include fetal Doppler applica-
tions, except for fetal heart rate monitors, should
follow track 3. Track 3 does not apply to systems
for which a display would be required but that
have fixed acoustic output.
Under track 3, acoustic output limits are not
determined on an application-specific basis, but
the global maximum derated ISPTA must be 720
mW/cm2 or less, and either the global maximum
MI must be 1.9 or less or the global maximum
derated spatial-peak pulse average intensity
must be 190 W/cm2 or less. An exception is for
ophthalmic use, in which case the TI = max(TIS,
TIC) and is not to exceed 1; the ISPTA.3 should be 50
mW/cm2 or less; and the MI is not to exceed 0.23.
The displayed TI and MI values are updated by
the machine as control settings are changed by
the operator (Figure 2). 
Guidelines for Safe Use 
Medical Endorsement 
Diagnostic ultrasound equipment should only be
used for medical diagnosis. Ultrasound equipment
should only be used by persons who are fully trained
in the safe and proper operation of the equipment (see
“Appendix” for a description of FDA-recommended
educational program content). The operator should
have a full awareness of machine settings and under-
stand the effect of those machine settings on thermal
and mechanical bioeffects. The initial power setting
and scanner default protocols should be set for lower
power. Exposure times and power levels should fol-
low the ALARA principle during scanning. 
J Ultrasound Med 2009; 28:139–150 143
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Table 2. Acoustic Intensity Output Measurement Parameters
Parameter Symbol Description
Spatial-peak temporal-peak ISPTP The highest intensity measured at any point in the ultrasound
beam and at any time; it is the highest value of the measured
intensities (more closely related to potential mechanical bioef-
fects and cavitation)
Spatial-peak pulse-average ISPPA The highest intensity measured at any point in the ultrasound
beam averaged over the temporal (time) duration of the pulse
Spatial-peak temporal-average ISPTA The highest intensity measured at any point in the ultrasound
beam averaged over the pulse repetition period (more closely
related to the magnitude of thermal bioeffects)
Spatial-average temporal-peak ISATP The average intensity over a selected area, such as the transducer
face, but at the peak in time
Spatial-average pulse-average ISAPA The average intensity over a selected area, such as the transducer
face, averaged over the temporal duration of pulse
Spatial-average temporal-average ISATA The average intensity over a selected area, such as the transducer
face, averaged over the pulse repetition period; this measure-
ment of intensity is frequently quoted and is the lowest value of
the measures of intensity
Definitions are given approximately in order of decreasing intensity value for the same pulse conditions.
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Thermal and Mechanical Indices 
As a general strategy, the on-screen TI and MI
values should be monitored after scanner adjust-
ments and kept ALARA. Although there is some
variation in opinions within the ultrasound bio-
effects community regarding the relationship
between acoustic output and acoustic bioeffects,
one might consider the following as suggested
guidelines for setting and monitoring acoustic
output during scanning. 
Prenatal Examinations 
1. Thermal index values less than 0.5 should be
used unless otherwise required, particularly
in the first trimester. 
2. More generally, TI values less than 0.5 likely
can be used for scanning times on an extend-
ed basis. 
3. Thermal index values greater than 0.5 and up
to 1 should be limited to scanning times less
than 30 minutes. 
4. Thermal index values greater than 2.5 should
be limited to scanning times less than 1 minute. 
5. Mechanical index values less than 0.4 should
be used if gas bodies may be present. 
6. In the absence of gas bodies, MI values can
be increased as needed but should remain
low because mechanisms for bioeffects not
related to gas bodies may be possible in the
developing fetus. 
Postnatal Examinations 
1. Thermal index values less than 2 likely can be
used for scanning times on an extended
basis. 
2. Thermal index values greater than 2 and up
to 6 should be limited to scanning times less
than 30 minutes. 
3. Thermal index values greater than 6 should
be limited to scanning times less than 1
minute. 
4. Mechanical index values less than 0.4 should
be used if gas bodies may be present. 
5. In the absence of gas bodies, MI values up to
1.9 (current FDA limit) can be used as needed. 
6. For neonatal studies, one should consider fur-
ther limiting exposure levels and durations as
developmental processes are continuing. 
Although these are suggested guidelines for set-
ting and monitoring acoustic output during
scanning, it is understood that depending on the
scanning conditions and diagnostic require-
ments of the study, these levels may be exceeded
144 J Ultrasound Med 2009; 28:139–150
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Figure 2. Examples of MI and TI displays on ultrasound images from various manufacturers (images courtesy of D. Pretorius, MD, University of
California, San Diego).
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for limited periods to obtain diagnostically
appropriate information and to ensure optimal
patient care.
Some nonimaging procedures, such as using
Doppler ultrasound for fetal heart monitoring or
peripheral pulse monitoring, use both continu-
ous wave and pulsed low-power output levels
that can cause tissue effects, although the exact
mechanisms are still not completely understood.
Low-intensity pulsed ultrasound effects, such as
bone fracture repair reported in humans and
repair of soft tissue damage and accelerated
nerve regeneration in animal models, indicate a
need for further research on potential fetal
effects (Stratmeyer et al,20 page 602).
In distinction to other medical imaging modali-
ties in which increases in imaging device output
generally improve image quality, it is worth keep-
ing in mind that the relationship between the
ultrasonic acoustic output, MI, and TI and image
and data quality is not always as straightforward
(Figure 3). Thus, always beginning with low MI
and TI values is a good overall strategy, only
increasing power as the needs of the study dictate.
For fetal scanning, the TIS should be used during
the first 8 weeks after conception, with the TIB
being used after 8 weeks. In the fetus and adult,
the TIS should be used for eye scanning. In neona-
tal, pediatric, and adult patients, the TIC should
be used when the ultrasound field is close to bone
in the skull, such as with transcranial Doppler
ultrasound, which uses higher power levels; oth-
erwise, the TIB should be used for everything else.
Special care and reduced scanning times
should be used for sensitive tissues such as those
found in the embryo (<8 weeks), eye, head, brain,
and spine. In general, prolonged pulsed Doppler
ultrasound is not recommended for these
sensitive tissues.2 The presence of a preexisting
temperature elevation, such as with elevated
maternal temperatures, should be considered
with regard to minimizing scan times, as should
the potential for probe self-heating.10
Finally, when the probe is held in a stationary
position, the freeze-frame (ie, nonimaging)
mode should be used. 
Nondiagnostic Imaging Applications 
Nondiagnostic uses of ultrasound equipment,
such as repeated scans of healthy subjects for
equipment demonstrations generally should be
avoided. First-trimester fetal scans should not
use color and power Doppler modes and should
not be performed for the sole purpose of pro-
ducing souvenir videos or photographs.
Production of fetal souvenir photographs or
videos during diagnostic clinical studies should
not increase exposure levels or extend scan times
beyond those needed for clinical purposes.
Operators should follow safe scanning guide-
lines and ALARA principles.
The FDA considers the promotion, selling, or
leasing of ultrasound equipment for making
“keepsake fetal videos” that are not part of a
medical diagnostic procedure to be an unap-
proved use of a medical device. Thus, the use of a
J Ultrasound Med 2009; 28:139–150 145
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Figure 3. Study in same patient (fetal age, 29 weeks) using different MI and TI values. Note that the overall study quality is not dra-
matically affected by the difference in MI and TI values, emphasizing the importance of beginning with lower acoustic output and
only increasing as necessary.
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diagnostic ultrasound system for these purposes,
without a physician’s order, may be in violation of
state laws or regulations.26
For ultrasound scanner training purposes, the
subject should be informed as to how the ultra-
sound scan relates to typical diagnostic studies.
During training sessions, frequent or extended
exposure of the same subject is to be avoided,
and the acoustic output should be kept as low as
possible.2
Conclusions 
Technological advances in ultrasound imaging
equipment provide improved visualization, diag-
nosis, and management. Such improvements have
substantially improved fetal, pediatric, and adult
patient imaging, especially prenatal management.
It is important to keep in mind that diagnostic
ultrasound transmits energy into the patient.
Diagnostic ultrasound studies of adult, pedi-
atric, and fetal patients generally are considered
safe. However, diagnostic procedures should be
performed only when there is a valid medical
indication.
Most diagnostic ultrasound procedures are per-
formed in the range of the guidelines suggested
here. For example, ultrasonic output levels during
routine obstetric ultrasound examinations as
reflected by the displayed MI and TI vales are gen-
erally low.27 However, higher output levels, partic-
ularly TI levels greater than 1.5, can be achieved,
especially with Doppler ultrasound, requiring
extra diligence even though they may account for
only a very small part of the examination time.28
More recent ultrasound scanning technology,
such as 3-dimensional sonography, can provide
clearer images of patient anatomy such as the
developing fetus that are recognizable to the fam-
ily and physician. Four-dimensional sonograph-
ic equipment further facilitates observing
movements similar to real-time 2-dimensional
imaging. Such capability potentially invites
longer viewing times, especially in the fetus.29
At present, 3-dimensional sonography likely does
not introduce additional safety considerations,
although 4-dimensional sonography with con-
tinuous exposure offers the potential to prolong
examination times and thus increase the poten-
tial for bioeffects.3
Patient scanning with ultrasound should use the
lowest possible acoustic output setting to obtain
the necessary diagnostic information under the
ALARA principle. The reader is referred to a series
of recent articles in the Journal of Ultrasound in
Medicine that provide an in-depth review of ultra-
sound bioeffects and exposimetry.19–23,30,31
Education of sonographers and sonologists is key
to maintaining a safe and productive ultrasound
scanning environment for patients. Unfortunately,
recent reports32 suggest that most ultrasound users
are poorly informed regarding ultrasound safety
issues, including the presence and location of MI
and TI information on the scanner display. Further
efforts in improving the education and training of
the ultrasound community are needed to increase
end user knowledge of the acoustic output of the
machines and safety issues (see “Appendix”). 
Summary 
The absence of human studies showing ultrasound
bioeffects leaves us to pose the question of why we
should be concerned about an as yet to be shown
potential for bioeffects from diagnostic ultrasound.
Fundamentally, the lack of an observed effect does
not implicitly suggest that there is no effect but only
implies that we have not been able, for whatever rea-
son, to detect one. This, although good news, does not
remove the responsibility all sonographers and sonol-
ogists have to actively advocate for their patients’
well-being by understanding the proper use of their
ultrasound scanners and biosafety considerations.
What is known at present is that ultrasound bioef-
fects have been shown in animal models under
acoustic output conditions similar to those used in
humans.10–23,30,31 We do not explicitly know how the
results of these studies relate to humans, but
because these studies raise the possibility of effects,
it is important to conduct diagnostic ultrasound
patient studies as safely as possible while we con-
tinue to gain additional information and insight
through basic and clinical research.
Diagnostic ultrasound equipment enhances the
care and treatment of patients and thus provides a
valuable and safe contribution to improving health
care when used in a thoughtful and appropriate
manner. Sonographers and sonologists have the
ultimate responsibility for the safe use of diagnos-
tic ultrasound equipment. 
146 J Ultrasound Med 2009; 28:139–150
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Appendix: US Food and Drug Administration Education Program on Ultrasound Systems Using the
ODS (Track 3)5
3.4. Track 3: Education Program 
1. 3.4.1. Provide an ALARA education program for the clinical end user that covers the subjects listed below; ALARA is an
acronym for the principle of prudent use of diagnostic ultrasound by obtaining the diagnostic information at an output that is
as low as reasonably achievable. This education program should include explanations of the following: 
a. The basic interaction between ultrasound and matter; 
b. The possible biological effects; 
c. The derivation and meaning of the indices; 
d. A recommendation to use and the need to follow the ALARA principle in all studies; 
e. Clinical examples of specific applications of the ALARA principle;
f. A document published by the American Institute of Ultrasound in Medicine, Medical Ultrasound Safety7
(new document forthcoming), which is acceptable to the FDA as meeting the generic content of the educa-
tional program. The manufacturer also should provide information specific to its device regarding ALARA.
2. 3.4.2. Minimum requirements for educational material for track 3 devices: 
a. 3.4.2.1. Bioeffects and biophysics of ultrasound interactions: 
i. Brief description of ultrasound, diagnostic frequencies, and energy levels; 
ii. Brief description of the change in policy that requires user education; 
iii. Short history of ultrasound use and safety record; 
iv. Potential hazards at high output levels; 
v. Biological effect mechanisms: thermal, mechanical; 
vi. Exposure-effect studies (range of outputs); 
vii. Risk versus benefit; 
viii. Present state of output levels: higher than historical levels;
ix. Proposed indices as indicators of thermal and mechanical effects. 
b. 3.4.2.2. Thermal mechanisms: 
i. Description of thermal bioeffects: temperature rise; 
ii. Tissue type (soft, bone, fluid) and relative absorption; 
iii. Transducer type (frequency, focusing) and relationship to exposure; 
iv. Attenuation, absorption, and scattering mechanisms in different tissue types; 
v. Spatial volume of insonified tissue (at focus or elsewhere): 
A. Homogeneity of tissue in an insonified volume (effects of layering); 
B. Soft tissue; 
C. Bone tissue (fetal, skull, other); 
D. Fluids and gas. 
c. 3.4.2.3. Nonthermal mechanisms: 
i. Description of mechanical effects: cavitation and role of bubbles; 
ii. Factors that produce cavitation: 
A. Pressure (compressional, rarefactional); 
B. Frequency; 
C. Beam focusing; 
D. Pulsed/continuous; 
E. Standing waves; 
F. Boundaries;
G. Type of material and ambient conditions. 
iii. Types of cavitation: 
A. Stable and inertial cavitation; 
B. Microstreaming;
C. Nucleation sites. 
iv. Threshold phenomena for different types of tissues;
v. Bioeffects data on animals (lung hemorrhage, intestinal hemorrhage). 
d. 3.4.2.4. Benefits of ultrasound versus risk: 
J Ultrasound Med 2009; 28:139–150 147
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i. Benefits of use; 
ii. Risk of use; 
iii. Risk from not using ultrasound; 
iv. Increase in risk as acoustic output increases; 
v. Increase in diagnostic information as acoustic output increases; 
vi. Increase in responsibility for user at higher output levels;
vii. The ALARA principle: 
A. Controlling energy; 
B. Controlling exposure time; 
C. Controlling scanning technique; 
D. Controlling system setup; 
E. Effects of system capabilities; 
F. Effects of operating mode (learn to distinguish);
G. Effects of transducer capabilities. 
e. 3.4.2.5. The ODS: 






iv. Thresholds for display of indices: 
A. eg, if system can exceed TI or MI of 1. 
v. System display levels: 
A. eg, minimum TI displayed, minimum MI displayed, display increments. 
vi. Explanation of the meaning of TI and MI: 
A. Threshold bioeffect levels vary depending on tissue type;
B. Bioeffect levels vary depending on frequency and pressure; 
f. 3.4.2.6 Practicing the ALARA principle: 
i. How to implement ALARA by using the TI and MI indices;
ii. Knowledge of system controls versus acoustic output: 
A. Overall gain and time-gain compensation versus increasing output; 
B. Dynamic range and postprocessing versus increasing output. 
iii. Knowledge of system applications versus output: 
A. Selection of appropriate range for task. 
iv. Knowledge of transducer effects on output: 
A. Frequency; 
B. Focusing; 
C. Pulse length; 
D. Dwell time (scanned versus unscanned). 
v. Knowledge of system operating mode versus output: 
A. B-mode; 
B. Doppler (spectral, color flow, amplitude Doppler); 
C. M-mode; 
D. Control exposure time; 
E. Use of the minimum possible to obtain information. 
vi. Clinical application examples: which indices are most important? 
A. Fetal, cranial; 
B. Fetal, Doppler; 
C. Adult, thyroid; 
D. Adult, carotid Doppler.
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